Bronchitis

Around 20% to 25% of individuals with rapidly declining FEV1/FVC trajectories experienced wheezing and usual phlegm/bronchitis as adolescents/young adults, according to results published in The Lancet Respiratory Medicine.

In 2022, chronic lower respiratory disease was the sixth highest cause of death in the U.S., according to results published in National Vital Statistics Reports.

Among adults with COPD and bronchitis, receiving 600 mg of tozorakimab every 4 weeks may lead to FEV1 improvement, according to a poster presented at the European Respiratory Society International Congress.

Four variables, including chronic bronchitis and high symptom burden, heightened the rate of exacerbations among patients with COPD and no recent exacerbations, according to results published in Annals of the American Thoracic Society.

SAN DIEGO — Among patients with COPD and heightened eosinophil levels, mepolizumab lowered annualized exacerbation rates, according to a presentation at the American Thoracic Society International Conference.

Individuals exposed to nitrogen dioxide and particulate matter less than 10 µm as a child faced elevated odds for bronchitic symptoms as an adult, according to results published in American Journal of Respiratory and Critical Care Medicine.

Transportation pollution puts children’s health at risk on a daily basis, but a switch to zero-emission vehicles and clean power would prevent several poor respiratory outcomes in this population, according to a press release.

Both a chronic productive cough and an intermittent productive cough were linked to poor lung function trajectories spanning from childhood to adulthood, according to study results published in The Lancet Respiratory Medicine.

Adolescent e-cigarette users had greater risk for bronchitic symptoms and shortness of breath even with consideration of simultaneous cigarette and cannabis use and secondhand exposure, according to results published in Thorax.